This drug can also enhance the acetylation of lysine 81 in the YB1 RNA-binding domain, thereby losing YB1-mediated translation activation, ultimately blocking the translation and synthesis of NRF2, G3BP1, and HIF1α in sarcoma cells mediated by MS-275, thereby inhibiting the progression of osteosarcoma (88). The gene discussed is YBX1; the disease is sarcoma.